# Nanoco Group awarded grant funding from Innovate UK for a rapid visual detection of SARSCoV-2

- Link: https://www.directorstalkinterviews.com/nanoco-group-awarded-grant-funding-from-innovate-uk-for-a-rapid-visual-detection-of-sarscov-2/412941402
- Published: 2020-11-25T07:21:16+00:00
- Author: Giles

**[Nanoco Group plc](https://www.directorstalkinterviews.com/company/nanoco-group-plc/nano.l)**(
[LON:NANO](https://www.directorstalkinterviews.com/company/nanoco-group-plc/nano.l)),
a world leader in the development and manufacture of cadmium-free quantum dots and
other nanomaterials emanating from its technology platform, has announced that it
has secured grant funding from Innovate UK, the UK’s innovation agency, for a life
sciences project to develop a heavy metal-free quantum dot testing kit for the accurate
and rapid visual detection of SARSCoV-2 (“Covid-19”).

The project builds on Nanoco’s existing capabilities in utilising quantum dots conjugated
with anti-bodies as a diagnostic tool in the detection of cancer (VIVODOTS® nanoparticles).
The project will specifically focus on anti-bodies for Covid-19 but, if successful,
the technology is expected to be applicable to other pathogens and potential future
variants of Covid-19.

The project will last 18 months with stage gates contingent on the success of the
R&D work. As part of the project, the company will explore opportunities to work
with downstream partners for a potential delivery system for the test. The testing
kit envisaged would potentially be self-administered with results produced in situ.
The project will cost just under £1.0m to which the Innovate grant contributes 80%
with the balance funded by Nanoco Group. After deducting incremental costs, the 
project is expected to have a neutral impact on the Group’s net cash flows in the
short term. Any medium term value implications will be wholly contingent on the 
successful delivery of the targeted project outcomes.

> **Brian Tenner, Nanoco Group’s CEO, commented:**
> “The Innovate grant is a welcome recognition of the potential for Nanoco’s CFQD
> ® Quantum Dots, configured as VIVODOTS® nanoparticles, to be used in bio-applications.
> The support from Innovate UK is critical to the continuation of our work in this
> area. While there is much to be done on the R&D phases of the project, it does
> create a potential third opportunity for future revenue, on top of the Group’s
> activities in Sensing and Display, whilst maintaining Nanoco’s cash runway.”

Share on:
